公开(公告)号：AU2007266535A1

公开(公告)日：2007-12-06

申请号：AU2007266535

申请日：2007-05-30

Applicant: ABBOTT LAB

Inventor： NELSON DEREK W ,  LI TONGMEI ,  FROST JENNIFER M ,  RYTHER KEITH B ,  PEDDI SRIDHAR ,  TIETJE KARIN ROSEMARIE ,  PEREZ-MEDRANO ARTURO ,  KOLASA TEODOZYJ ,  GALLAGHER MEGAN E ,  PATEL MEENA V ,  CARROLL WILLIAM A ,  FLORJANCIC ALAN S ,  DART MICHAEL J

IPC: C07D277/46 ,  A61K31/426 ,  A61K31/427 ,  A61K31/428 ,  A61K31/429 ,  A61P29/00 ,  C07D277/48 ,  C07D277/60 ,  C07D277/82 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D513/04

Abstract: The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and L1 are defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1a, R2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

公开(公告)号：ZA200602274B

公开(公告)日：2007-11-28

申请号：ZA200602274

申请日：2006-03-17

Applicant: ABBOTT LAB

Inventor： ANWER BASHA ,  DART MICHAEL J ,  JIANGUO JI ,  RYTHER KEITH B ,  MORTELL KATHLEEN H ,  SCHRIMPF MICHAEL R ,  BUNNELLE WILLIAM H ,  GALLAGHER MEGAN E ,  PACE JENNIFER M ,  TIETJE KARIN R ,  NERSESIAN DIANA L ,  TAO LI

IPC: A61K20090101 ,  A61K31/435 ,  A61P20090101 ,  A61P25/00 ,  C07D20090101 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08

Abstract: Compounds of formula (I) Z-Ar 1 -Ar 2 wherein Z is a diazabicyclic amine, Ar 1 is a 5- or 6-membered aromatic ring, and Ar 2 is selected from the group consisting of an unsubstituted or substituted 5-or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazoyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by ±7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

公开(公告)号：ES2226844T3

公开(公告)日：2005-04-01

申请号：ES00932445

申请日：2000-05-15

Applicant: ABBOTT LAB

Inventor： SCHRIMPF MICHAEL R ,  SIPPY KEVIN B ,  DAANEN JEROME F ,  RYTHER KEITH B ,  JI JIANGUO

IPC: C07D491/048 ,  A61K31/00 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/4545 ,  A61K45/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  C07D401/04 ,  C07D495/04

Abstract: Un compuesto de fórmula I **(Fórmula)** o las sales farmacéuticamente aceptables del mismo donde, Z es **(Fórmula)** R1 y R2 se seleccionan independientemente del grupo formado por hidrógeno y alquilo; A y B están independientemente ausentes o se seleccionan independientemente del grupo formado por alquenilo, alcoxi, alcoxicarbonilo, alquilo, alquinilo, carboxi, haloalquilo, halógeno, hidroxi, e hidroxialquilo; R3 se selecciona del grupo formado por **(Fórmula)** R4 se selecciona del grupo formado por hidrógeno, alquilo, y halógeno; R5 se selecciona del grupo formado por hidrógeno, alcoxi, alquilo, halógeno, nitro, y -NR10R11 donde R10 y R11 se seleccionan independientemente del grupo formado por hidrógeno y alquilo inferior; R6 se selecciona del grupo formado por hidrógeno, alquenilo, alcoxi, alcoxialcoxi, alcoxialquilo, alcoxicarbonilo, alcoxicarbonilalquilo, alquilo, alquilcarbonilo, alquilcarboniloxi, alquiltio, alquinilo, amino, aminoalquilo, aminocarbonilo, aminocarbonil-alquilo, aminosulfonilo, carboxi, carboxialquilo, ciano, cianoalquilo, formilo, formilalquilo, haloalcoxi, haloalquilo, halógeno, hidroxi, hidroxialquilo, mercapto, mercaptoalquilo, nitro, 5-tetrazolilo, -NR7SO2R8, -C(NR7)NR8R9, -CH2C(NR7)NR8R9-, -C(NOR7)R8, -C(NCN)R7, -C(NNR7R8)R9, -S(O)2OR7, y -S(O)2R7; y R7, R8, y R9 se seleccionan independientemente del grupo formado por hidrógeno y alquilo, donde alquilo inferior es un alquilo C1-C4 de cadena lineal o ramificada, alquilo es alquilo C1-C10 de cadena lineal o ramificada, alquenilo es alquenilo C2-C10 de cadena lineal o ramificada, alquinilo es alquinilo C2-C10 de cadena lineal o ramificada y amino es un grupo -NR20R21 donde R20 y R21 se selecciona independientemente entre hidrógeno, alquilo y alquilcarbonilo.

公开(公告)号：AU2004274492A1

公开(公告)日：2005-03-31

申请号：AU2004274492

申请日：2004-09-17

Applicant: ABBOTT LAB

Inventor： BUNNELLE WILLIAM H ,  DART MICHAEL J ,  TIETJE KARIN R ,  SCHRIMPF MICHAEL R ,  RYTHER KEITH B ,  GALLAGHER MEGAN E ,  NERSESIAN DIANA L ,  MORTELL KATHLEEN H ,  PACE JENNIFER M ,  BASHA ANWER ,  JI JIANGUO

IPC: C07D471/04 ,  A61K31/435 ,  A61P25/00 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08

Abstract: Compounds of formula (I) Z-Ar 1 -Ar 2 wherein Z is a diazabicyclic amine, Ar 1 is a 5- or 6-membered aromatic ring, and Ar 2 is selected from the group consisting of an unsubstituted or substituted 5-or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazoyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by ±7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

公开(公告)号：DE60011895D1

公开(公告)日：2004-08-05

申请号：DE60011895

申请日：2000-05-15

Applicant: ABBOTT LAB

Inventor： SCHRIMPF MICHAEL R ,  SIPPY KEVIN B ,  DAANEN JEROME F ,  RYTHER KEITH B ,  JI JIANGUO

IPC: C07D491/048 ,  A61K31/00 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/4545 ,  A61K45/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  C07D401/04 ,  C07D495/04

Abstract: Heterocyclic substituted aminoazacyclic compounds of the formula (I):Z-R3, wherein Z is a defined aminoazacycle and R3 is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.

公开(公告)号：ES2209825T3

公开(公告)日：2004-07-01

申请号：ES00906998

申请日：2000-01-25

Applicant: ABBOTT LAB

Inventor： BUNNELLE WILLIAM H ,  CRISTINA DANIELA BARLOCCO ,  DAANEN JEROME F ,  DART MICHAEL J ,  MEYER MICHAEL D ,  RYTHER KEITH B

IPC: A61K31/00 ,  A61K31/407 ,  A61K31/4355 ,  A61K31/4365 ,  A61K31/439 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/502 ,  A61P9/10 ,  A61P15/10 ,  A61P25/00 ,  A61P25/02 ,  A61P25/06 ,  A61P25/08 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  C07D401/08 ,  C07D471/08 ,  C07D487/08 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00 ,  A61K31/395

Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein: V is selected from the group consisting of a covalent bond and CH2; W is selected from the group consisting of a covalent bond, CH2 and CH2CH2; X is selected from the group consisting of a covalent bond and CH2; Y is selected from the group consisting of a covalent bond, CH2 and CH2CH2; Z is selected from the group consisting of CH2 and CH2CH2, and CH2CH2CH2; L1 is selected from the group consisting of a covalent bond and (CH2)n; n is 1-5; R1 is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), and (l); R2 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, aminoalkyl, aminocarbonylalkyl, benzyloxycarbonyl, cyanoalkyl, dihydro-3-pyridinylcarbonyl, hydroxy, hydroxyalkyl, phenoxycarbonyl, and -NH2; are useful for controlling synaptic transmission in mammal.

公开(公告)号：SI1147112T1

公开(公告)日：2004-04-30

申请号：SI200030295

申请日：2000-01-25

Applicant: ABBOTT LAB

Inventor： BUNNELLE WILLIAM H ,  CRISTINA DANIELA BARLOCCO ,  DAANEN JEROME F ,  DART MICHAEL J ,  MEYER MICHAEL D ,  RYTHER KEITH B ,  SCHRIMPF MICHAEL R ,  SIPPY KEVIN B ,  TOUPENCE RICHARD B

IPC: A61K31/00 ,  A61P25/00 ,  C07D401/08 ,  C07D471/08 ,  C07D487/08 ,  C07D519/00 ,  A61K31/395

公开(公告)号：DK0970083T3

公开(公告)日：2003-08-11

申请号：DK98907359

申请日：1998-02-05

Applicant: ABBOTT LAB

Inventor： WASICAK JAMES T ,  GARVEY DAVID S ,  HOLLADAY MARK W ,  RYTHER KEITH B ,  LIN NAN-HORNG

IPC: A61P25/04 ,  A61K31/422 ,  A61K31/4439 ,  A61K31/4725 ,  A61P25/00 ,  A61P43/00 ,  C07D487/04 ,  A61K31/44

Abstract: 7a-Substituted hexahydro-1H-pyrrolizine compounds having the formula wherein A is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to selectively control synaptic transmission in mammals.

公开(公告)号：DK0950057T3

公开(公告)日：2003-03-10

申请号：DK97952392

申请日：1997-12-10

Applicant: ABBOTT LAB

Inventor： HOLLADAY MARK W ,  ARNERIC STEPHEN P ,  BAI HAO ,  DART MICHAEL J ,  LYNCH JOHN K ,  OR YAT SUN ,  RYTHER KEITH B ,  SULLIVAN JAMES P ,  WASICAK JAMES T ,  EHRLICH PAUL P ,  LIN NAN-HORNG

IPC: A61P25/04 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/485 ,  A61P25/28 ,  A61P29/00 ,  C07D205/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  A61K31/44

Abstract: The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula (I) or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula (I) which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.

公开(公告)号：ES2171222T3

公开(公告)日：2002-09-01

申请号：ES96914786

申请日：1996-05-28

Applicant: ABBOTT LAB

Inventor： HOLLADAY MARK W ,  LIN NAN-HORNG ,  RYTHER KEITH B ,  HE YUN

IPC: A61K31/00 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4439 ,  A61P25/00 ,  A61P25/04 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12

Abstract: Novel 3-pyridyloxymethyl heterocyclic ether compounds having formula (I), wherein * is a chiral center and n, X, R , R , A andB are specifically defined, which are useful in controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions therof; and use of said compositions to selectively control synaptic transmission in mammals.